Co-Diagnostics (NASDAQ:CODX) Inc has announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test is now available for sale in the UK after being validated according to the United Kingdom Health Security Agency's (UKHSA) Medical Devices Regulations 2021 under Coronavirus Test Device Approvals (CTDA).
The company said the Logix Smart test is available for sale through Clent Life Science, Co-Diagnostics authorized distributor in the UK.
“Since the pandemic began, we have been on the forefront of providing gold-standard PCR solutions across the world, including Europe,” Co-Diagnostics CEO Dwight Egan said in a statement.
READ: Co-Diagnostics says its CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test
“We believe that each additional validation of our company's testing technology continues to demonstrate the quality of our patented CoPrimer platform, and the valuable role we have been fortunate enough to play in improving the quality of life for people affected by the pandemic through providing accurate, reliable, and cost-effective COVID-19 testing products,” Egan added.
Co-Diagnostics (NASDAQ:CODX) noted that its test is validated for use with several sample types, including saliva.
Co-Diagnostics’ proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through its enhanced detection of genetic material. Because the company owns its platform, it is able to accomplish this faster and more economically, allowing for wider margins while still positioning Co-Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.
Contact Sean at sean@proactiveinvestors.com